A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy

Area of Science:

• Oncology
• Virology
• Molecular Biology

Background:

• Tumor hypoxia creates a resistant cell population, challenging conventional radio- and chemotherapies.
• Hypoxia-inducible factor (HIF) regulates cellular responses to low oxygen by binding to hypoxia-responsive elements (HRE).

Purpose of the Study:

• To develop a novel therapeutic strategy targeting the hypoxic fraction of solid tumors.
• To engineer a hypoxia- and HIF-dependent oncolytic adenovirus for selective cancer cell lysis.

Main Methods:

• Development of a hypoxia/HIF-dependent replicative adenovirus (HYPR-Ad).
• Assessing E1A expression under hypoxic conditions.
• Evaluating conditional cytolysis of hypoxic versus normoxic cells.

Main Results:

• The HYPR-Ad demonstrated hypoxia-dependent E1A expression.
• Selective lysis of hypoxic tumor cells was observed, with minimal impact on normoxic cells.
• Proof-of-principle for a hypoxia-selective oncolytic adenovirus was established.

Conclusions:

• An attenuated oncolytic adenovirus selectively targeting hypoxic cells can be generated.
• This HYPR-Ad approach shows potential for treating solid tumors characterized by hypoxia.
• The therapeutic strategy is applicable across diverse tumor types irrespective of origin or genetic makeup.